In one paragraphReview in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
31 authors.
Christine Lee-PoturalskiCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio.ORCID 0009-0000-1096-5146 Madelyn DirrimCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio.ORCID 0009-0003-9304-6963 Jadyn StewartDepartment of Radiation Oncology, University of Maryland Baltimore School of Medicine, Baltimore, Maryland.ORCID 0009-0002-3321-8826 Douglas CaruthersDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-0163-422X Kathy HentrichDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0009-0004-3342-4181 Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-9265-0283 Phuoc TranDepartment of Radiation Oncology, University of Maryland Baltimore School of Medicine, Baltimore, Maryland.ORCID 0000-0002-0147-0376 Nicole SimoneDepartment of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-7662-7470 Amit SawantDepartment of Radiation Oncology, University of Maryland Baltimore School of Medicine, Baltimore, Maryland.ORCID 0000-0002-3901-5774 Julie SchwarzDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-2407-7531 Clifford RobinsonDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-1399-9904 Yasmin HasanDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois.ORCID 0009-0003-5815-7465 Jennifer YuDepartment of Radiation Oncology and Department of Cancer Biology, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-0244-4014 Lei RenDepartment of Radiation Oncology, University of Maryland Baltimore School of Medicine, Baltimore, Maryland.ORCID 0009-0005-2384-5676 Luigi MarchionniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-7336-8071 Geoffrey HugoDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-4109-8177 Jean L NakamuraDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-2097-9223 Xiaofeng YangDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia.ORCID 0000-0001-9023-5855 Joseph O DeasyDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-9437-266X Ralph R WeichselbaumDepartment of Radiation and Cellular Oncology and Ludwig Center for Metastases Research, University of Chicago, Chicago, Illinois.ORCID 0000-0002-5643-8939 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4MTranslational and Clinical Trial Correlates CoreU54CA274513 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI Jennifer S Yu · 2022 to 2026
$9.3MRadiation Effect on Immune Cells and the MicrobiomeU54CA274291 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Joseph O Deasy · 2022 to 2026
$9.1MResource Sharing CoreU54CA273956 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Luigi Marchionni · 2022 to 2026
$8.9MShared Resource Core 2: Clinical Artificial Intelligence CoreU54CA274516 · NCI · DANA-FARBER CANCER INST · PI DAPHNE A. HAAS-KOGAN, Franziska Michor · 2023 to 2026
$8.1MWashington University (WU) ROBIN Center: MicroEnvironment and Tumor Effects Of Radiotherapy (METEOR)U54CA274318 · NCI · WASHINGTON UNIVERSITY · PI Clifford Grant Robinson · 2023 to 2026
$7.7MTumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLCR01CA271540 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Phuoc T. Tran · 2023 to 2026
$2.3MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA271540NCI NIH HHS U54 CA273956NCI NIH HHS U54 CA274291NCI NIH HHS U54 CA274318NCI NIH HHS U54 CA274513NCI NIH HHS U54 CA274516
6 · The paper itselfAbstract
The Radiation Oncology-Biology Integration Network (ROBIN) initiative addresses critical gaps in radiation oncology by integrating advanced biological research, technologic innovation, and clinical practice. ROBIN leverages "omics" technologies, data science, and integrative analyses to elucidate the mechanisms governing tumor and normal tissue responses to radiotherapy (RT). Through five specialized centers-OligoMET, ImmunoRad, GenRad, METEOR, and KIDSROBIN-the network covers a broad spectrum of cancer and radiation biology research. Each center conducts translational programs linked to clinical trials, targeting key domains, including metastasis biology, RT-immune system interactions, and genomic determinants of treatment response. KIDSROBIN assures the invaluable inclusion of pediatric cancers to the consortium. By collecting clinically annotated human biospecimens and applying single-cell and spatially resolved omics, ROBIN enables mechanistic insights into radiation effects directly in patients. A central pillar of the initiative is its commitment to data standardization and sharing, using cloud-based platforms to generate accessible and interoperable datasets. ROBIN also prioritizes education and cross-disciplinary training to cultivate the next generation of scientists in radiation biology and oncology. This integrated approach positions ROBIN to drive transformative advances in radiation oncology and multimodal cancer therapy, informing personalized treatment strategies and improving patient outcomes. This review provides an overview of the ROBIN program and its key strategies, research activities, and contributions to advancing radiation biology and oncology. The vision and leadership of Dr. Norman Coleman have been foundational to the development of the ROBIN initiative, inspiring a collaborative ecosystem that bridges science and clinical practice to drive meaningful impact in patient care.
Indexed as
NeoplasmsRadiation OncologyRadiobiologyGenomicsHumansTranslational Research, Biomedical
Identifiers
PMID41941260
PMCPMC13138140
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390